REVIEW ARTICLE - BRAIN TUMORS



Prevalence of incidental meningiomas and gliomas on MRI: a meta-analysis and meta-regression analysis

Satoshi Nakasu^{1,2} · Akifumi Notsu³ · Yoko Nakasu²

Received: 26 April 2021 / Accepted: 14 June 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021

Abstract

Background The chance of incidentally detecting brain tumors is increasing as the utilization of magnetic resonance imaging (MRI) becomes more prevalent. In this background, knowledge is accumulating in relation to the prediction of their clinical sequence. However, their prevalence—especially the prevalence of glioma—has not been adequately investigated according to age, sex, and region.

Method We systematically reviewed the articles according to the PRISMA statement and calculated the prevalence of meningiomas and diffuse gliomas in adults using a generalized linear mixed model. Specifically, the differences related to age, sex, and region were investigated.

Results The pooled prevalence of incidental meningiomas in MRI studies was 0.52% (95% confidence interval (CI) [0.34–0.78]) in 37,697 individuals from 36 studies. A meta-regression analysis showed that the prevalence was significantly higher in elderly individuals, women, and individuals outside Asia; this remained statistically significant in the multivariate meta-regression analysis. The prevalence reached to 3% at 90 years of age. In contrast, the prevalence of gliomas in 30,918 individuals from 18 studies was 0.064% (95%CI [0.040 - 0.104]). The meta-regression analysis did not show a significant relationship between the prevalence and age, male sex, or region. The prevalence of histologically confirmed glioma was 0.026% (95%CI [0.013-0.052]).

Conclusions Most of meningiomas, especially those in elderlies, remained asymptomatic, and their prevalence increased with age. However, the prevalence of incidental gliomas was much lower and did not increase with age. The number of gliomas that developed and the number that reached a symptomatic stage appeared to be balanced.

Keywords Asymptomatic · Glioma · Incidental · Meningiomas · MRI

Introduction

The chance of incidentally detecting brain tumors is increasing as the utilization of magnetic resonance imaging (MRI) becomes more prevalent in research and clinical practices. Among incidental tumors, meningiomas, pituitary

This article is part of the Topical Collection on Brain Tumors

- ¹ Division of Neurosurgery, Kusatsu General Hospital, Kusatsu, Japan
- ² Department of Neurosurgery, Shiga University of Medical Science, Ohtsu, Japan
- ³ Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan

adenomas, schwannomas, and gliomas were assessed by MRI [50]. The accumulated knowledge on the natural course of these incidental asymptomatic brain tumors is still not sufficient to predict the future growth of individual tumors. Although it is assumed that early detection and treatment can improve survival, this hypothesis has not been validated [37, 60, 65]. On the other hand, both risks associated with treatment and psychological stress trigger dilemmas in patients with incidental tumors under a wait-and-see strategy [26, 50].

Very few meta-analyses have analyzed the prevalence of incidental brain tumors other than pituitary adenomas [13, 43]. Morris et al. reported that the prevalence of different types of incidental brain tumors among 19,599 individuals was as follows: meningiomas, 0.29%; pituitary adenomas,0.15%; vestibular schwannomas, 0.03%; and gliomas, 0.05% [43]. Conversely, Ezza et al. reported that

Satoshi Nakasu neuro-nakasu@kfx.biglobe.ne.jp

the prevalence of pituitary adenoma on imaging studies is as high as 22.5% [13]. The difference was due to MRI protocols including thin section section-coronal and -sagittal plains. Other meta-analyses reported a rate of brain tumors as a whole and did not describe the prevalence of each type of tumor [15]. The reported prevalence varied according to the age of the population and the male–female ratio in each study. The prevalence may also change according to the region targeted in the search. Such subgroup analyses of incidental brain tumors have been insufficient, although more than 20 studies have reported the prevalence of incidental brain tumors on MRI [1, 3–5, 7, 9, 16, 18–21, 24, 28–31, 34, 36, 39, 42, 54, 56, 57, 59, 61, 63] since the review by Morris et al. [43].

Although majority of incidental meningiomas are known to be indolent, the selection of patients who are suitable for treatment is still controversial [49]. The elucidation of the prevalence and age distribution of incidental meningiomas is important for predicting the possibility of symptomatic growth of meningiomas. Asymptomatic incidental meningiomas were found in 1.3–2.3% of autopsy studies [48, 55]. These data may not be applicable to a modern population because the studies were performed more than 30 years previously based on the data that were mainly obtained more than 50 years previously. Actually, from 1985 to 2019, the age-adjusted incidence of meningioma in the US population increased more than three times, 2.5/100,000-year in 1985 [22] vs. 8.33 in 2019 [38]. The increased incidence might be explained by alterations in the population composition, exposure to risk factors, and the widespread use of imaging studies. However, the true frequency of asymptomatic meningioma in the same period has not been elucidated.

Recent studies discussed the strategy to treat gliomas that were found incidentally [41, 60]. Gliomas are one of the most frequently encountered brain tumors, but they are rarely diagnosed during the asymptomatic phase. It is not known how often incidental gliomas become symptomatic because the prevalence of asymptomatic gliomas has not been clarified. Previous reports about the prevalence of incidental gliomas contained very few patients, and the majority of the cases were not histologically proven [3]. Furthermore, previous systematic reviews included not only diffuse gliomas (diffuse astrocytic and oligodendroglial tumors) but also other types of gliomas such as pilocytic astrocytomas and gangliogliomas [43]. The recent WHO classification clearly distinguishes the latter because of the different molecular and clinical features [40].

In this meta-analysis, we selected asymptomatic meningiomas and gliomas as candidates for the comparison of clinical implications, because they have a comparable clinical incidence but a different prevalence on MRI, and they are associated with controversial management issues that clinicians often encounter. Pituitary adenomas and vestibular schwannomas were excluded from this study because the patients with these tumors were often symptomatic, with accompanying manifestation of which they were unaware.

We systematically reviewed the relevant literature and calculated the prevalence of meningiomas and diffuse gliomas. Specifically, the difference among age groups, sex, and study regions was investigated.

Methods

Literature search and data extraction

The present study followed the PRISMA statement. The search flow diagram is outlined in Supplementary file 1. We searched for relevant English articles using the keywords "magnetic resonance OR MRI", "brain", and "incidental OR asymptomatic" and published from 1990 to November 2020 in PubMed, Scoups, and Google Scholar; "meningioma", "glioma", "tumor", or "neoplasm" were combined key words. The search was performed on November 24, 2020. The exact search strategy has been described in Supplementary file 1. Although studies confined to familial tumor syndromes such as neurofibromatosis were excluded, studies in patient groups with comorbidities (such as trauma, heart diseases, or migraine) were included when such findings were incidentally identified. We incorporated studies that recruited ≥ 100 participants with a mean age of ≥ 20 years. Two of the authors searched the relevant literature independently, and final selection was determined by discussion.

Risk of bias

The majority of incorporated studies were descriptive cross-sectional studies that reported the number of cases in a particular population at a time point or during a period of time. We used the JBI critical appraisal checklist for studies reporting prevalence data, which was developed as a tool for conducting systematic reviews of prevalence, to evaluate the risk of bias (Supplementary file 2) [45]. The adequate sample size was calculated by putting precision (*d*) as a half of expected prevalence, which was 1% for meningiomas and 0.1% for gliomas [47]. The adequate sample size was calculated to be 1520 for meningiomas and 15,200 for gliomas.

We estimated the publication bias using a funnel plot. As the assessment in traditional funnel plot is known to be inappropriate for the proportional studies with rare events, the estimate was performed using the method described by Hunter et al. [23]

Extraction of incidence data

In each study, we collected the mean age, sex (male ratio = the number of men/total population), and the numbers of meningiomas and diffuse gliomas. Follow-up results and histological diagnoses were also recorded if available. Pilocytic astrocytomas, gangliogliomas, and ependymomas were excluded from diffuse gliomas. When only the median age was recorded, the median value was used instead of the mean (two studies). In two studies in which only the age range was described (60 to 64 years, and 17 to 82 range), we used 62 years and 49.5 years, respectively, as the mean age. We grouped the regions from which the studies originated as Asia (Japan, Taiwan, and China) and other regions because white and black Americans had a significantly higher incidence of benign meningiomas in comparison to Native Americans and Asian/Pacific Islanders [12]. The studies were divided into small (< 500 participants) or large and normal participants (normal volunteer or health checkup) or participants with specific comorbidities (symptoms or diseases not related to incidental findings [e.g., cardiac disease, diabetes, dysmenorrhea, or migraine]).

Statistical analysis

We used the R software program (v4.03) to perform the statistical analyses. A random-effects model was applied in the meta-analysis. We used the "metaprop" function in R to perform a single-arm meta-analysis to calculate prevalence. Because several studies reported a null incidence, we initially used Freeman-Tukey double arcsine transformation. The results of the meta-analysis based on the back-transformation of the Freeman-Tukey double arcsine transformation can be erroneously smaller than all individual study results, especially in cases that include diverse sample sizes [58]. For this reason, we used the generalized linear mixed model (GLMM) with maximum-likelihood method. A GLMM can directly calculate the prevalence without transformation and has advantages in meta-analyses that include null incidence. The confidence intervals for individual studies were calculated by the Clopper-Pearson method.

The reviewed studies were tested for heterogeneity (I^2 statistic), and meta-regression analyses were performed to identify factors related to heterogeneity. Two-sided P values of <0.05 were considered to indicate statistical significance.

Ethical approval & informed consent.

This review did not involve direct studies on humans, and informed consent was not required.

Results

After removing duplicates, we retrieved 125 articles for fulltext assessment to determine their eligibility (Supplementary Fig. 1). Articles with symptomatic tumors, without radiological diagnosis, CT studies, and overlapping data were excluded. Studies without an adequate MR sequence or whole-body MRI using a body coil were also excluded. As a result, we selected 35 articles and added 1 through crossreferencing. We analyzed the frequency of meningiomas in 36 studies [1, 3–5, 7, 9, 16, 18–21, 24, 25, 27–36, 39, 42, 44, 52, 54, 56, 57, 59, 61–64, 66] and of gliomas in 34 studies [1, 3–5, 9, 16, 18–21, 24, 25, 27–29, 31–36, 39, 42, 44, 52, 54, 56, 57, 59, 61–64, 66] (Table 1, Supplementary File 3).

Meningiomas

The prevalence of incidental meningiomas in MRI studies was 0.52% (95% confidence interval (CI) [0.34–0.78], $I^2 = 80.7\%$) in a total of 37,697 individuals (Table 2) (Fig. 1a). The funnel plot and regression test did not detect a publication bias (P=0.69) (Supplementary file 4). A subgroup analysis revealed a significant difference between Asia (0.22%, 95%CI [0.10–0.51] and other regions (0.66%, 95%CI [0.43–1.02] (P=0.022) (Fig. 1a). We found no difference between large and small studies (large 0.56% [0.32–0.98] vs. small 0.59% [0.35–1.0], P=0.89) or studies in healthy participants and those with comorbidity (healthy 0.42% [0.24–0.75] vs. comorbidity 0.81% [0.48–1.4], P=0.10).

The results of meta-regression analyses were concordant with the results of subgroup analyses (Table 3). The prevalence was affected by the mean age (P < 0.0001) (Fig. 1b), male ratio (P = 0.0046), and region (P = 0.017). The multivariable meta-regression analysis showed statistically significant differences in mean age (P = 0.0004), male ratio (P = 0.012), and region (P = 0.043) (Table 3).

Gliomas

The prevalence of incidental gliomas in MRI studies was 0.071% (95%CI [0.045–0.110], $I^2 = 0\%$) in a total of 34,763 individuals (Fig. 2a). A funnel plot, however, showed moderate asymmetry with a significant regression test (P=0.006) (Fig. 2b). As shown in the funnel plot, some of the small-sized studies (< 500 participants) had a relatively high prevalence. Considering the publication bias due to the small-study effect, we excluded these small-sized studies from the subsequent analyses. Consequently, the prevalence in 30,918 individuals in 18 studies is calculated to be 0.064% (95%CI [0.040–0.104]) in Table 2. A funnel plot of the large-sized

Table 1 Summary of analyzed articles	yzed articles									
Author, year [reference]	Participants	Total number	Mean age	Male ratio	Menin	Glm	Other mass lesions	Treatment	Study type	Region
Alturkustani 2020 [1]	Adult migraine	275	M38,	0.418	4	1	Subep 1, Pit 2	Resect except for 1	С	Middle East
Boss 2016 [3]	\geq 45 years, in the Netherlands	5800	m64.9 SD10.9	0.449	143	9	Ggoma 1 Subep 1	Glm, 5 wait and see, 1 rad; Menin, 8 resect, 7 rad	Н	Euro
Boutet 2017 [4]	PROOF study, volun- teers.≥65 years	503	m75.3 SD0.9	0.414	10	1	Sch 1	Astro, biopsied; Menin, observe	Н	Euro
Brugulat-Serrat 2017 [5]	Normal first-degree descendants of Alzhei- mer patients	575	m56.0 (45–75)	0.395	10	0	clb mass 1, Pit2, Subep1	NA	C	Euro
Cerhan 2019 [7]	Mayo clinic study of aging	2402	m75	0.526	52	NA	NA	NA	Н	USA
Cieszanowski 2014 [9]	Asymptomatic persons with special pri- vate health insur- ance, ≥ 18 years	666	m46.4 (20–77)	0.698	ε	-	NA	Glm resect, 1; Menin resect	Н	Euro
Glasmacher 2019 [16]	Patients attending early-onset cognitive disorder clinic	514	M60.5	0.501	7	1	Pit 1, Sch 1 DNET 1,	Glm, observ., Menin observ	C	Euro
Haberg 2016 [18]	50–66 years, HUNT study	1006	m58.5	0.473	10	1	Pit 3, Sch 1	1 mixed Glm resect; Menin, 2 resect	Н	Euro
Hartwigsen 2010 [19]	Young healthy volun- teers in brain research imaging studies	206	m25.68 SD5.72	0.568	0	0	NA	NA	Н	Euro
Hedderich 2020 [20]	Prematurely born adults. Bavarian Longitudinal Study and control	206	m26.8 SD0.7	0.573		0	3 suspicious FLAIR high mass lesion	NA	C	Euro
Hegenscheid 2013 [21]	The German population- based study of health in Pomerania	2500	m53 (21–88)	0.492	6	7	Met 1, Pit 9, Sch 1	NA	Н	Euro
Ikeda 2002 [24]	Brain check-up	2312	m53.5 /SD11	0.689	ŝ	7	Pit 3, Sch 1, lymphoma 1	2 Glm, resect (GBM, Astro); Menin 1 surg	Н	Asia
Illes 2004 [25]	Normal adult control	151	m47.1 (18–90)	0.543	0	0	NA	NA	Н	NSA
Katzman 1999 [27]	Volunteers participated various NIH research as control	1000	m30.6 (3–83)	0.546	0	7	Pilo 1	Glm 1 resect (oligo) 1 observ.;	Н	USA
Keuss 2019 [28]	The 1946 British birth cohort	471	m70.2 SD0.7	0.512	ŝ	0	Subep 1	Menin, observ	Н	Euro
Konc 2018 [29]	Australian twin study > 65 years	400	m70.4	0.35	9		Undefined cystic mass 1, Subep 1	NA	Н	Australia

Multic part [reference]Parial partialMultic part [reference]Multic part [reference	Table 1 (continued)										
1Residence in Vienne, org (3 Y-3) with mini- (3 Y-3) with mini- (4 Y-3) with	Author, year [reference]	Participants	Total number	Mean age	Male ratio	Menin			Treatment	Study type	
Abruntian capital errit13mage0.23730Pit 43 Menit observeHAyryndroutis persins138m54 SD7.550.85510Pit 1.8ch1NAHAyryndroutis persins138m54 SD7.550.85510Pit 1.8ch1NAHAyryndroutis persins2164m51.80.8550.85510Pit 1.8ch1NAHAryndroutis persins2164m51.80.570.46150NANAHAryndroutis persins2164m51.80.4520.46150NANAHAryndroutis persins206m54.80.4520.46150NANAHAryndroutis medical132m58.80.4210.470NANANANAAryndroutis medical132m58.80.430.47NANANANAAryndroutis medical100m33.87D.50.491NANANANAAryndroutis medical100m33.87D.50.491NANANANAArinary digge000m33.87D.50.4901NANANANAArinary digge000m33.87D.50.491NANANANANAArinary digge000m33.87D.50.4901NANANANAArinary digge000m33.87D.50	Krampla 2004 [24]	Residents in Vienna, age 75 years	532	m75	0.402	6	NA	NA	Menin, 1 surgery, 8 observ., minimal growth in 1	Н	Euro
Ayruptomatic persons138 $m54$ SD7.550.85510NANAHstereturbscreeturbscreeturbscreeturbscreeturbscreeturbNAHStereturb obycinanse2164 $m51$ 0.57 14 0Pit1, Sh1NAHStereturbscreeturb862 $m59.25$ SD2.72 0.461 50NANAHTraibou longitudinal862 $m39.25$ SD2.72 0.461 50NANAHTraibou longitudinal802 $m39.25$ SD2.55 0.452 71Pit2NAHThe menop system300 $m23.8$ SD2.5 0.42 00NANAHAyruptomatic neckeul12 $m56.6$ 0.441 0NNANAHAyruptomatic neckeul100 $m31.55$ 0.42 0NNANANAHAyruptomatic neckeul100 $m56.6$ 0.441 1NNANANAHAyruptomatic neckeul100 $m31.55$ 0.42 0NNANANAHAyruptomatic neckeul100 $m56.6$ 0.441 1NNANANANAAyruptomatic neckeul100 $m31.55$ 0.421 0.41NANANANAStatisty statisty vith backetio203 0.422 0.41 1Pit3.54614NANAStatisty statisty vith backetio203 </td <td>Kumar 2008 [31]</td> <td>Australian capital terri- tory and Queanbeyan</td> <td>478</td> <td>range (60–64)</td> <td>0.527</td> <td>б</td> <td>0</td> <td>Pit 4</td> <td>3 Menin observ</td> <td>Н</td> <td>Australia</td>	Kumar 2008 [31]	Australian capital terri- tory and Queanbeyan	478	range (60–64)	0.527	б	0	Pit 4	3 Menin observ	Н	Australia
Self-refered body-inneg2164m51.8 0.57 14 0 $Pit 1$, $Sch 1$ NA H Taizbeu longitudi562m59.25 SD2.72 0.461 5 0 Na Na H Taizbeu longitudi562m59.25 SD2.72 0.461 5 0 Na Na H Taizbeu longitudi512m78.4 0.452 0.461 0.452 0.461 0.420 Na Na H Taizbeu longitudi320m23.8 SD2.5 0.461 0.420 0.420 0.841 0.420 Na Na Na Asymptomate medical132m56 0.441 0.420 0.41 0.420 0.420 0.441 0.420 <	Laible 2012 [32]	Asymptomatic persons in routine health screening	138	m54 SD7.55	0.855	-	0	NA	NA	Н	Euro
	Lee W-J 2008 [32]	Self-referred body-imag- ing center	2164	m51.8	0.57	14	0	Pit 1, Sch 1	NA	Н	Asia
The memory and aging introvy (age 70-39)32 $m74$ 0.452 71 $P12$ NAHPrimary (age 70-39)mad control30m23.8 S10.5000ch mass 1NACPrimary (age 70-39)mad control33m23.8 S10.5000ch mass 1NACAsymptomatic medical122 $m36$ 0.841 00NANAHAsymptomatic medical122 $(38-32)$ 0.41 0NANAHAsymptomatic medical100 $m31.5$ 0.14 10NANAHNeurologically normal100 $m31.5$ 0.42 01NANAHNeurologically normal100 $m31.5$ 0.437 61Pi1.3.1.pi1.41CIII. resect. Menin. 4H1Rain checkup400 $m20$ 0.437 61Pi1.3.1.pi1.41CIII. resect. Menin. 4H1Control participants in tibular symptoms20 $m32.6 S10.5$ 0.437 0.6 NANANANA7Lobitian Birth cohort70 $m22.5 S10.5$ 0.526 5 0 0.7 0.841 NANAH7Lobitian Birth cohort70 $m72.5 S10.5$ 0.526 5 0 0.841 0.841 0.847 0.849 0.841 7Lobitian Birth cohort70 $m72.5 S10.5$ 0.526 5 0 0.841 0.864	Li S 2018 [34]	Taizhou longitudinal study, age 55–65 years	562	m59.25 SD2.72	0.461	Ś	0	NA	NA	Н	Asia
Primary dysmemorrhea340 $m23.85D2.5$ 000chmase 1NACand controlmode controlm560.84100NANAHAvyruptomatic medical132 63^8-8_7 0.84100NANAHAvyruptomatic medical132 63^8-8_7 0.42 01NANAHKealthy volunters100 $m29$ 0.42 0.1410NANAHNeurologically normal00 $m356$ 0.42° 0.1410NANAHStatio breck-up4000 $m56$ 0.497 6 1Pit 3. Epid 1Gim, resect (atypical)CStatio breck-up00 $m356$ 0.497 6 1Pit 3. Epid 1Gim, resect (atypical)CStatio sympoons 0.4835 0.505 12NANAHIControl participants in203 $m21.95032$ 0.453 0.555 1 2 NANAHILothian Birth cohort700 $m72.55015$ 0.555 0.555 0.66 0.66 NMNAHILothian Birth cohort700 $m72.55015$ 0.5526 5 0.74 0.75 NMNANAILothian Birth cohort700 $m72.55015$ 0.526 5 0.76 NMNANANAILothian Birth cohort700 $m72.55015$ 0.526	Li W 2010 [35]	The memory and aging study (age 70–89)	542	m78.4	0.452	٢	1	Pit 2	NA	Н	Australia
Asymptomatic medical132 $m56$ 0.84100NANAHdoctors0 $(38-82)$	Li WC 2015 [36]	Primary dysmenorrhea and control	330	m23.8 SD2.5	0	0	0	clb mass 1	NA	C	Asia
Healthy volunteers100 $n29$ 0.42 0.42 0.14 1 NA <td>Lo 2008 [39]</td> <td>Asymptomatic medical doctors</td> <td>132</td> <td>m56 (38–82)</td> <td>0.841</td> <td>0</td> <td>0</td> <td>NA</td> <td>NA</td> <td>Н</td> <td>Asia</td>	Lo 2008 [39]	Asymptomatic medical doctors	132	m56 (38–82)	0.841	0	0	NA	NA	Н	Asia
Neurologically normal a dults with headache100 $m31.5$ 0.14 1 0 NA Menin, resect (atypical) C 1Brain check-up4000 $m56$ 0.497 6 1 $Pit3.Epid1$ $Gim, resect, Menin, 4$ H 541Brain check-up4000 $m56$ 0.497 6 1 $Pit3.Epid1$ $Gim, resect, Menin, 4$ H 541 Patients with audio-ves-200 $Rage (17-82)$ 0.505 1 2 NA NA A C 541 rbultar symptoms 203 $m21.9$ SD3.2 0.453 0.6 0.7 NA NA H 71 Lothian Birth colort700 $m72.5$ SD1.5 0.526 5 0 $Chumor 1, Pit2$ $Observ$ H 71 Lothian Birth colort700 $m72.5$ SD1.5 0.526 5 0 $Chumor 1, Pit2$ $Observ$ H 71 Lothian Birth colort700 $m72.5$ SD1.5 0.526 5 0 $Chumor 1, Pit2$ $Observ$ H 71 Lothian Birth colort700 $m72.5$ SD1.5 0.526 5 0 $Chumor 1, Pit2$ $Observ$ H 71 Lothian Birth colort700 $m72.5$ SD1.5 0.526 5 0 $Chumor 1, Pit2$ $Observ$ H 71 Lothian Birth colort700 $m72.5$ SD1.5 0.526 5 0 $Chumor 1, Pit2$ $Observ$ D 70 Multiple sciansis 0.666 $m49.5$ <	Menzler 2010 [42]	Healthy volunteers	100	m29	0.42	0	1	NA	NA	Η	Euro
Brain check-up400 $m56$ 0.497 6 1 $Pit3. Epid 1$ $GIm. rescet; Menin, 4$ H Patients with audio-ves-200 $Range (17-82)$ 0.505 1 2 NA NA C Patients with audio-ves-200 $Range (17-82)$ 0.505 1 2 NA NA C Control participants in203 $m21.9 SD3.2$ 0.453 0 0 NA NA H Control participants in203 $m21.9 SD3.2$ 0.453 0 0 NA NA H Uothian Birth cohort700 $m72.5 SD1.5$ 0.526 5 0 $Chumor 1, Pit 2$ $Observ. Gim.$ H 1936 Candidates referred for733 $m49.8 SD18.68$ 0.517 19 1 $Pit 9, Met 1, Sch 2$ $Observ. Gim.$ C $MRI of the orbito-Totom45.8 SD18.680.517191Pit 9, Met 1, Sch 2Observ. Gim.CMRI of the orbito-Totom45.70.24720NANANAMultiple sclerosis166m45.70.24720NANANANAMultiple sclerosis166Mat 5.70.50920.68310.5040.5040.5040.5040.5040.504Multiple sclerosis10NANANANANA0.5040.5040.5040.5040.504$	Mullaly 2018 [44]	Neurologically normal adults with headache	100	m31.5 (18–56)	0.14	-	0	NA	Menin, resect (atypical)	C	NSA
Patients with audio-ves-200Range (17–82)0.50512NANACibular symptoms203m21.9 SD3.20.4530.60512NACControl participants in studies on the effects of the drug exstary203m21.9 SD3.20.4530.4530.4530.453NACLothian Birth cohort700m72.5 SD1.50.52650clb tumor 1, Pit 2Observ.H1936Candidates referred for paranasal or temporal753m49.8 SD18.680.517191Pit 9, Met 1, Sch 2Menin, observ.; Glm, observCMRI of the orbitol- paranasal or temporal760m45.70.24720NANACMultiple sclerosis166m45.70.24720NANACHealthy adults with brain1113m52.6 SD8.50.68310Pit 3, Epid 1ObservMLobeck up1113m52.6 SD8.50.683100Pit 3, Epid 1ObservCDiabetes type 2 patients289m570.50920temporal loberT2 highMenin, observC	Onizuka 2001 [52]	Brain check-up	4000	m56 (24–85)	0.497	9	1	Pit 3, Epid 1	Glm, resect; Menin, 4 surgery, 2 observ	Н	Asia
Control participants in studies on the effects of the drug cestasy203m21.9 SD3.20.45300NAHStudies on the effects of the drug cestasy700m72.5 SD1.50.52650clb tumor 1, Pit 2ObservHJ936Lothian Birth cohort700m72.5 SD1.50.52650clb tumor 1, Pit 2ObservHNRI of the orbito- paramasal or temporalm49.8 SD18.680.517191Pit 9, Met 1, Sch 2Menin, observ; Glm, observCMultiple sclerosis166m45.70.24720NANACMultiple sclerosis113m52.6 SD8.50.68310Pit 3, Epid 1ObservHHealthy aduts with brain1113m52.6 SD8.50.68310Pit 3, Epid 1ObservCDiabetes type 2 patients289m570.50920temporal lobe T2 highMenin, observCage 40-75module, Pit 1module, Pit 1module, Pit 1Menin, observC	Papanikolau 2010 [54]	Patients with audio-ves- tibular symptoms	200	Range (17–82)	0.505	1	7	NA	NA	C	Euro
Lothian Birth cohort700m72.5 SD1.50.52650clb tumor 1, Pit 2ObservH1936Candidates referred for733m49.8 SD18.680.517191Pit 9, Met 1, Sch 2Menin, observ; Glm, CCMRI of the orbito- paranasal or temporal66m45.70.24720NACCMultiple sclerosis166m45.70.24720NANACCHealthy adults with brain1113m52.6 SD8.50.68310Pit 3, Epid 1ObservHCheck-up1113m52.6 SD8.50.50920Pit 3, Epid 1ObservCDiabetes type 2 patients289m570.50920temporal lobe T2 highMenin, observCage 40-75age 40-75nodule, Pit 1nodule, Pit 1NaC	Reneman 2012 [56]	Control participants in studies on the effects of the drug ecstasy	203	m21.9 SD3.2	0.453	0	0	NA	NA	Н	Euro
Candidates referred for MRI of the orbito- paranasal or temporal753m49.8 SD18.680.517191Pit 9, Met 1, Sch 2Menin, observ; Glm, observCMRI of the orbito- paranasal or temporal0m45.70.24720NANACMultiple sclerosis patients and control166m45.70.24720NANACHealthy adults with brain1113m52.6 SD8.50.68310Pit 3, Epid 1ObservH0Diabetes type 2 patients289m570.50920temporal lobe T2 highMenin, observCage 40-75age 40-75nodule, Pit 1nodule, Pit 1noneerC	Sandeman 2013 [57]	Lothian Birth cohort 1936	700	m72.5 SD1.5	0.526	S	0	clb tumor 1, Pit 2	Observ	Н	Euro
Multiple sclerosis166m45.70.24720NACpatients and controlCHealthy adults with brain1113m52.6 SD8.50.68310Pit 3, Epid 1ObservH0Diabetes type 2 patients289m570.50920temporal lobe T2 highMenin, observCage 40-75	Serag 2020 [59]	Candidates referred for MRI of the orbito- paranasal or temporal bones	753	m49.8 SD18.68	0.517	19	1	Pit 9, Met 1, Sch 2	Menin, observ.; Glm, observ	U	Middle East
Healthy adults with brain1113m52.6 SD8.50.68310Pit 3, Epid 1ObservHcheck-up0Diabetes type 2 patients289m570.50920to be the total observe to the total observe to the total observe to the total observe total observet	Trufyn 2014 [61]	Multiple sclerosis patients and control	166	m45.7	0.247	7	0	NA	NA	C	Canada
Diabetes type 2 patients 289 m57 0.509 2 0 temporal lobe T2 high Menin, observ C age 40-75 nodule, Pit 1	Tsushima 2005 [62]			m52.6 SD8.5	0.683	-	0	Pit 3, Epid 1	Observ	Н	Asia
	Vázquez-Justes 2020 [63]	Diabetes type 2 patients age 40–75	289	m57	0.509	7	0	temporal lobe T2 high nodule, Pit 1	Menin, observ	C	Euro

(continued)	
le 1	
Tab	

~										
Author, year [reference] Participants	Participants	Total number Mean age	Mean age	Male ratio	Menin	Glm	Male ratio Menin Glm Other mass lesions Treatment	Treatment	Study type Region	Region
Weber 2009 [64]	All applicants for mili- tary flying duties	2536	m 20.5 (17–35)	1	0	-	Pilo, CPA1, 4th ventricle Observ mass 1	Observ	Н	Euro
Yue 1997 [66]	Cardiovascular dis- ease≥65 years	3672	m75.1	0.417 19	19	0	Pit 6	4 Menin, resect,	C	USA

Glm glioma, Menin, meningioma, Study type: C, participants with comorbidity or specific disease; H, healthy volunteer or asymptomatic patients in health check-up; Astro, astrocytoma; CPA, cerebellopontine angle tumor; clb, cerebellar; Epid, epidermoid; Ggoma, ganglioglioma; Met, metastasis; Pilo, pilocytic astrocytoma; Pit, pituitary adenoma; Sch, schwannoma; Subep, subspendymoma; M, median; m, mean; SD, standard deviation; rad, radiotherapy; Euro, Europe; NA, not available; observ., observation; resect, resection studies showed slight asymmetry, which did not show statistical significance in a regression test (P=0.41).

In the meta-regression analysis, we detected no significant differences in the mean age (P=0.79) (Fig. 2c), male ratio (P=0.73), regions (P=0.10), participants (P=0.48), or study size (P=0.48) (Table 3).

In addition, we calculated the prevalence of histologically proven gliomas. The prevalence was 0.026% (95%CI [0.013–0.052], $I^2 = 0\%$) in 30,918 participants. The following tumors were histologically confirmed: astrocytoma, n=3; oligodendroglioma, n=1; mixed glioma, n=1; lowgrade gliomas, n=1; high-grade glioma (a pontine tumor diagnosed from clinical course), n=1; and glioblastoma (a patient with mild cognitive dysfunction who might have been symptomatic), n=1. On the other hand, we noticed that several authors described suspicious mass lesions that showed hyperintensity on FLAIR without a diagnosis [18, 20, 63]. These lesions are not included in this analysis; however, they are included in Table 1.

Sensitivity analysis

The leave-one-out method (excluding each study one-by-one from the analysis) did not substantially change the pooled prevalence of meningiomas, which ranged from 0.49 to 0.59% (I^2 85.4–90.4%). The most influential study was a study in young men [64]. Although this study contained no meningioma cases, despite the large study population (n = 2536), we did not exclude the study because of the results of the meta-regression analyses.

In gliomas, the leave-one-out method showed that the change in pooled prevalence ranged from 0.06 to 0.073% with no change of l^2 .

Discussion

In this study, we showed the prevalence of incidental meningiomas and gliomas on MRI. Meningioma was found in 0.52% of the studied populations. In contrast, the prevalence of glioma was much lower (0.064%). Each of the included studies targeted different populations with regard to age, sex, and region. Thus, we were able to analyze factors related to prevalence by a meta-regression analysis without individual data. In meningiomas, the prevalence changed with age, male ratio, and region, whereas the prevalence of glioma was not likely to be influenced by these factors.

Meningiomas

Previous studies reported that incidental meningiomas were found more frequently in elderly individuals and women. However, those reports rarely showed the exact age and sex

Table 2 Summary of study population

	Meningiomas	Diffuse gliomas
Analyzed studies	36 studies N = 37,697	18 studies N=30,918
Prevalence	0.52% 95%CI [0.34–0.78]	0.064% 95%CI [0.040–0.104]
Gender	Male 20,126 Female 17,571	Male 16,917 Female 14,001
Mean age	56.97 years	56.30 years
Region	Asia 7 (Japan 3, China 3, Taiwan 1), Other 29 (USA 6, Europe 18, Australia 3, Middle East 2)	Asia 5 (Japan 3, China 1, Taiwan 1), Other 13 (USA 2, Europe 10, Middle East 1)
Participants	Healthy, 25 studies With comorbidity, 11 studies	Healthy, 14 studies With comorbidity, 4 studies

CI confidence interval

distribution because the majority of the studies lacked data of the whole cohort, with the exception of autopsy studies. The prevalence of meningioma in this study (0.52%) was higher in comparison to that in the meta-analysis by Morris (0.29%) [43] because the latter included studies in pediatric populations. We showed that age was strongly associated with prevalence (Fig. 2c), with the prevalence in the population of > 90 years of age approaching 3%. Although the rate is slightly lower in comparison to the value reported in an autopsy study (4.6% in individuals of \geq 80 years of age) [48], some of the cases involving small meningiomas that were found on autopsy might have been missed on MRI. Despite the increase in the number of cases of clinically diagnosed meningiomas, the frequency of asymptomatic meningiomas in each age group is not likely to increase in comparison to the era of autopsy studies, which were based on the data obtained between 1950 and 1983 [48]. Consequently, recent increase in the incidence of meningiomas is likely due to the increase in the number of radiologically diagnosed tumors.

A report based on the SEER database showed that the incidence of meningiomas was lowest in Native Americans and relatively low in Asians and Pacific islanders [12]. This may be due to an identification bias, because the Central Brain Tumor Registry of the United States (CBTRUS) showed that > 50% of meningiomas were radiologically diagnosed [53]; Native American and Asian people may be less likely to undergo MRI; thus, incidental meningiomas may be less frequently diagnosed. Because there were no studies in Native Americans, we investigated the difference between Asian (actually obtained from East Asia) and non-Asian regions and found a difference in the prevalence of incidental meningiomas on MRI.

Gliomas

Diffuse gliomas (astrocytomas, oligodendrogliomas, and their malignant forms) were included in this study. The prevalence of diffuse glioma was 0.064%, when lesions that the authors diagnosed as glioma were included. However, the prevalence of histologically confirmed gliomas was 0.023% (including one clinically diagnosed tumor). Håberg cautioned that most cases in which glioma initially suspected were found to be false positives [18]. In their 13 cases in which low-grade glioma was initially suspected, one was found to be astrocytoma after resection; after additional imaging studies, the other 12 lesions were gliosis (n=6), cyst (n=2) and benign unspecific lesions (n=4). Thus, lesions that were defined as glioma without histological confirmation might not actually be glioma. On the contrary, suspicious mass lesions that showed hyperintensity on FLAIR without histological confirmation [18, 20, 63] might have been gliomas. Thus, the prevalence of diffuse glioma was at least 0.023% and probably 0.054%.

Although various age groups, male ratios, and regions were included in this study, the heterogeneity of the pooled estimate of glioma prevalence was very low. We found no significant differences in age, sex, or region. Although epidemiological studies showed high incidence rates in males [53], clinical studies on incidental glioma showed a female preponderance [17]. Incidental gliomas in females might have slower growth or be less likely to be symptomatic in comparison to those in males.

Comparison with epidemiological studies

Epidemiological studies reported the incidence rate and prevalence of meningioma. The age adjusted incidence rate was reported to be 4.5–5.6/100,000 person-years [6, 8, 11, 14]), while that of CBTRUS in a middle-age or older

Fig. 1 The results of the meta-analysis of studies on meningioma. a A forest plot of the prevalence of incidental meningiomas on MRI. Studies from Asia showed a lower prevalence in comparison to those from other region (P=0.022). **b** The mean age and prevalence of incidental meningiomas on MRI. A metaregression analysis revealed a significant association between the mean age and prevalence. $(y = \exp(0.051 \times -8.1)/(1 + \exp)$ $(0.051 \times -8.1)), P < 0.0001).$ The size of the balloon represents the size of each study. Gray balloon, study in Asia

а			Events per 100		
Study	Events	Total	observations	Events	95%-CI
non-Asia					
Boss 2016	143	5800		2.47	[2.08; 2.90]
Yue 1997	19	3672 -			[0.31; 0.81]
Weber 2006	0	2536 -		0.00	[0.00; 0.15]
Hegenscheid 2013	9	2500 -			[0.16; 0.68]
Cerhan 2019	52	2402		2.16	[1.62; 2.83]
Haberg 2016	10	1006			[0.48; 1.82]
Katzman 1999	0	1000		0.00	[0.00; 0.37]
Serag 2020	19	753	· · · ·	2.52	[1.53; 3.91]
Sandeman 2013	5	700 -			[0.23; 1.66]
Cieszanowski 2014	3	666 —	·		[0.09; 1.31]
Brugulat-Serrat2017	10	575	· · · ·		[0.84; 3.18]
Li W 2010	7	542	·		[0.52; 2.64]
Krampla 2004	9	532			[0.78; 3.19]
Glasmacher 2019	2	514 —			[0.05; 1.40]
Boutet 2017	10	503			[0.96; 3.63]
Kumar 2008	3	478 —			[0.13; 1.82]
Keuss 2019	3	471 —	·		[0.13; 1.85]
Konic 2018	6	400	-		[0.55; 3.24]
Vázquez-Justes 2020	2	289 —	-		[0.08; 2.48]
Alturkustani 2020	4	275			[0.40; 3.68]
Hartwigsen 2010	0	206 -	<u>:</u>		[0.00; 1.77]
Hedderich 2020	1	206 —	:		[0.01; 2.67]
Reneman 2012	0	203	÷		[0.00; 1.80]
Papanikolau 2010	1	200 —			[0.01; 2.75]
Trufyn 2014	2	166 —			[0.15; 4.28]
Illes 2004	0	151			[0.00; 2.41]
Labile 2012	1	138 —			[0.02; 3.97]
Menzler 2010	0	100			[0.00; 3.62]
Mullaly 2018	1	100 —	-		[0.03; 5.45]
Random effects model		7084		0.66	[0.43; 1.01]
Heterogeneity 12 = 73%,	$1 \ge 0.85$	20, p < 0.0	1		
Asia P = 0.022					
Onizuka 2001	6	4000 🕂		0.15	[0.06; 0.33]
Ikeda 2002	3	2312 +	·	0.13	[0.03; 0.38]
Lee 2008	14	2164		0.65	[0.35; 1.08]
Tsushima 2005	1	1113 +	-	0.09	[0.00; 0.50]
Li S 2018	5	562 -		0.89	[0.29; 2.06]
Li WC 2015	0	330 H	<u>. </u>		[0.00; 1.11]
Lo 2008	0	132	<u>.</u>		[0.00; 2.76]
Random effects model		0613 🗢	•	0.22	[0.10; 0.51]
Heterogeneity $12 = 67\%$,	$\tau 2 = 0.62$	000, p < 0.0	D1		
Random effects mode		37697	÷	0.52	[0.34; 0.78]
Heterogeneity: I ² = 81%, 1	² = 1.0534			1	
		0	1 2 3	4	

population was reported to be much higher (17.8/100,000 person-years) [53]. This is because > 50% of the population with CBTRUS had radiologically diagnosed meningiomas. Annually, 5–12 patients were treated per 100,000 population among middle-age and older individuals in a UK study. That study reported that the incidence rate and prevalence of meningiomas increased with age [6] (Fig. 3a). On the other hand, incidental meningiomas were found on MRI in > 1% of patients of \geq 70 years of age and reached 3% in patients of > 90 years of age (Fig. 3a). It is assumed that

many meningiomas develop even in old age and that most remain asymptomatic with a slow growth rate.

In epidemiological studies, the estimated age-adjusted incidence rates of glioma were 4.5 to 6.1 per 100,000 persons-years [2, 10, 51]. Although the incidence rate is comparable to that of meningiomas, the prevalence of incidental gliomas on MRI was much lower in comparison to the prevalence of meningioma (Fig. 3b). This was partly because incidental glioblastomas were very rarely detected on MRI because glioblastoma is a rapidly growing tumor that has a

Fig.1 (continued)




 Table 3
 Results of the meta-regression and multivariate meta-regression analyses

Meta-regression	Estimate	р
Meningiomas		
Mean age	0.051 [0.026-0.075]	< 0.0001
Male ratio	-3.24 [-5.48 to -1.00]	0.0046
Region	1.15 [0.205-2.09]	0.02
Study size	-0.339 [-1.200.525]	0.44
Participants	-0.462 [-1.32-0.399]	0.29
Multivariate meta-regression		
Mean age	0.039 [0.017-0.060]	0.0004
Male rate	-2.80 [-4.95 to -0.626]	0.012
Region	0.80 [0.026-1.57]	0.043
Diffuse gliomas*		
Mean age	-0.0041 [-0.034 to-0.026]	0.79
Male ratio	-0.523 [-3.54-2.50]	0.73
Region	1.02 [-0.208-2.24]	0.10
Participants	0.670 [-0.791-2.13]	0.37

Estimate=logit transformed value; *CI*, confidence interval; ^{*}the results was calculated in large-size studies ($N \ge 500$); [], 95% confidence interval

small chance of being detected in the incidental phase. We have to be cautious about such a "length-time bias". The prevalence of tumors with rapid growth is estimated to be lower than the true value, because, in screening studies that take several years to recruit participants, patients with malignant tumors would not be recruited before the manifestation of symptoms.

The most prominent difference between the prevalence of incidental meningiomas and gliomas on MRI was the distribution in age groups. The prevalence of incidental meningiomas increased markedly with age, while that of glioma did not. If a part of incidental tumors remains asymptomatic, their prevalence on MRI is expected to increase with age when new development is constant. In gliomas, development and symptomatic growth appear to balance out, and most of incidental gliomas become symptomatic with a latent period; another interpretation is that—while part of gliomas remain asymptomatic—the asymptomatic phase of gliomas becomes much shorter with age due to their more rapid malignant change.

Limitations

The present study was associated with some limitations. One critical limitation of this study is the lack of histological confirmation in the majority of cases. Although a dura-based mass with typical radiological features rarely has a histology other than meningiomas [46], it is difficult to diagnose glioma with a conventional MRI sequence. For this reason, we analyzed the incidence of histologically proven gliomas.

Fig. 2 The results of the metaanalysis of studies on glioma. a A forest plot showing the prevalence of incidental gliomas on MRI. Smaller studies (S, < 500) often had a larger prevalence although the difference was not statistically significant (P=0.59). **b** A funnel plot showing moderate asymmetry (P=0.006). c The mean age and prevalence of incidental gliomas on MRI. A meta-regression analysis revealed a non-significant relationship between the mean age and prevalence. $(y = \exp(-0.004 \times -7.1))$ $(1 + \exp(-0.004 \times -7.1)),$ P=0.79). The size of the balloon represents the size of each study. Gray balloon, study in Asia

а			Events non 100		
Study	Events	Total	Events per 100 observations	Ev	ents 95%-Cl
oluuj	Lionto	rotui			
Larger study				-	
Boss 2016	6	5800 +			.103 [0.038; 0.225]
Onizuka 2001	1	4000 +			.025 [0.001; 0.139]
Yue 1997	0	3672 -			.000 [0.000; 0.100]
Weber 2006	1	2536 +			.039 [0.001; 0.220]
Hegenscheid 2013	2	2500 +			.080 [0.010; 0.289]
Ikeda 2005	2	2312 +	-		.087 [0.010; 0.312]
Lee WJ 2008	0	2164 <u>–</u>			.000 [0.000; 0.170]
Tsushima 2005	1	1113	-		.000 [0.000; 0.331]
Haberg 2016 Katzman 1999	2	1008			.099 [0.003; 0.553] .200 [0.024; 0.721]
Serag 2020	2	753			.133 [0.003; 0.738]
Sandeman 2013	0	700			.000 [0.000; 0.526]
Cieszanowski 2014	1	666			.150 [0.004; 0.834]
Brugulat-Serrat 2017	0	575			.000 [0.000; 0.639]
Li S 2018	0	562			.000 [0.000; 0.654]
Li W 2010	1	542 +			.185 [0.005; 1.024]
Glasmacher 2019	1	514 +			.195 [0.005; 1.079]
Boutet 2017	1	503 ++			.199 [0.005; 1.103]
Random effects model	-	30918			
Heterogeneity $I2 = 0\%$,			0	Ľ	0.064 [0.040; 0.104]
Smaller study					
Kumar 2008	0	478 -		0	
Keuss 2019	0	470			.000 [0.000; 0.769] .000 [0.000; 0.780]
Konic 2018	1	400 +			.250 [0.006; 1.385]
Li WC 2015	0	330			.000 [0.000; 1.112]
Vázguez-Justes 2020	0	289			.000 [0.000; 1.268]
Alturkustani 2020	1	275			.364 [0.009; 2.009]
Hartwigsen 2010	0	206			.000 [0.000; 1.775]
Hedderich	0	206			.000 [0.000; 1.775]
Reneman 2012	0	203			.000 [0.000; 1.801]
Papanikolau 2020	2	200 -			.000 [0.121; 3.565]
Trufyn 2014	0	166			.000 [0.000; 2.198]
Illes 2004	0	151 -			.000 [0.000; 2.413]
Labile 2012	0	138			.000 [0.000; 2.638]
Lo 2008	0	132 -			.000 [0.000; 2.756]
Menzler 2010	1	100 -			.000 [0.025; 5.446]
Mullaly 2018	0	100 -			.000 [0.000; 3.622]
Random effects model	3	845 🤄	>		0.100 [0.022; 0.456]
Heterogeneity I2 = 0%, τ	-)		
Random effects mode		34763		0	.071 [0.045; 0.110]
Heterogeneity: $I^2 = 0\%$, τ^2	- 0 0822			U	.071 [0.045; 0.110]
1000000000000000000000000000000000000	- 0.0622,	p = 0.97	0.5 1 1.5 2 2.5	3	
		0	0.0 1 1.0 2 2.0		

Another problem is the study size. We calculated that the adequate study size was 1250 for meningioma and 12,500 for glioma. A minority of the studies on meningioma and none of the studies on gliomas reached an adequate size. Although the synthesized population reached > 30,000, the small studies on gliomas tended to report a higher prevalence. Because the prevalence of gliomas is very low, small studies with positive findings might be relatively easily published. In contrast, smaller studies are more likely suppressed from publication if their results are not impressive. Consequently, the pooled prevalence might be skewed to be

higher. Although we excluded studies on glioma with < 500 participants, this might have been insufficient. While a previous meta-analysis included low-volume studies with even less than 100 cases [43], such a small-study effect should be cautiously considered when the calculated incidence is very low.

One possible problem is that the majority of population-based studies had a recruitment period of one to several years. Participants with a rapidly growing incidental tumor who wait months for MRI may become symptomatic. Such a length-time bias is not related

Fig. 2 (continued)





Fig. 3 Comparison between the prevalence of incidental tumors on MRI and epidemiological studies. **a** The prevalence of incidental meningioma and the age-adjusted incidence rate in an epidemiological study in UK [6]. **b** The prevalence of incidental gliomas and the age-adjusted incidence rate in an epidemiological study in the USA [52]



to the prevalence of meningiomas, which generally show slow growth; however, it is related to some gliomas, which may grow rapidly with possible malignant transformation.

Conclusions

We performed a meta-analysis to investigate the prevalence of incidental brain tumors on MRI using GLMM. The pooled prevalence of incidental meningiomas was 0.52% (95% CI [0.34–0.78]). A meta-regression analysis showed that the prevalence was significantly higher in the elderly, females, and in non-Asian areas; the findings remained significant in the multivariate analysis. The prevalence increased markedly with age and reached to approximately 3% at > 90 years of age. In contrast, the prevalence of diffuse gliomas was low (0.064%), while the reported incidence rates of clinically diagnosed meningioma and diffuse glioma were comparable. The prevalence of incidental gliomas was not related to age, male sex, or region.

Most of meningioma, especially those in the elderly, remained asymptomatic, and their incidence increased with age. In contrast, the prevalence of incidental gliomas was much lower and did not increase with age. The number of gliomas that developed and the number that grew to a symptomatic stage appeared to be balanced.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00701-021-04919-8.

Acknowledgements We would like to thank Mr. Brian Quinn (Japan Medical Communication) for editing a draft of this manuscript.

Declarations

Conflict of interest The authors declare no competing interests.

References

- Alturkustani A, Bock Y, Bajunaid K, Lingawi S, Baeesa S (2020) Significant incidental brain magnetic resonance imaging findings in migraine headache patients: retrospective cross-sectional study. Clin Neurol Neurosurg 196:106019. https://doi.org/10.1016/j. clineuro.2020.106019
- Arora RS, Alston RD, Eden TOB, Estlin EJ, Moran A, Birch JM (2009) Age–incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 11:403– 413. https://doi.org/10.1215/15228517-
- Bos D, Poels MMF, Adams HHH, Akoudad S, Cremers LGM, Zonneveld HI, Hoogendam YY, Verhaaren BFJ, Verlinden VJA, Verbruggen JGJ, Peymani A, Hofman A, Krestin GP, Vincent AJ, Feelders RA, Koudstaal PJ, Van Der Lugt A, Ikram MA, Vernooij MW (2016) Prevalence, clinical management, and natural course of incidental findings on brain MR images: the population-based Rotterdam scan study. Radiology 281:507–515. https://doi.org/ 10.1148/radiol.2016160218
- Boutet C, Vassal F, Celle S, Schneider FC, Barthelemy JC, Laurent B, Barral FG, Roche F (2017) Incidental findings on brain magnetic resonance imaging in the elderly:the PROOF study. Brain Imaging Behav 11:293–299. https://doi.org/10.1007/ s11682-016-9519-4
- Brugulat-Serrat A, Rojas S, Bargallo N, Conesa G, Minguillon C, Fauria K, Gramunt N, Molinuevo JL, Gispert JD (2017) Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. BMJ Open 7:e013215. https://doi.org/10.1136/bmjopen-2016-013215
- Cea-Soriano L, Wallander MA, Garcia Rodriguez LA (2012) Epidemiology of meningioma in the United Kingdom. Neuroepidemiology 39:27–34. https://doi.org/10.1159/000338081

- Cerhan JH, Butts AM, Syrjanen JA, Aakre JA, Brown PD, Petersen RC, Jack CR Jr, Roberts RO (2019) Factors Associated With Meningioma Detected in a Population-Based Sample. Mayo Clin Proc 94:254–261. https://doi.org/10.1016/j.mayocp.2018.07. 026
- Champeaux C, Weller J, Katsahian S (2019) Epidemiology of meningiomas. A nationwide study of surgically treated tumours on French medico-administrative data. Cancer Epidemiol 58:63–70. https://doi.org/10.1016/j.canep.2018.11.004
- Cieszanowski A, Maj E, Kulisiewicz P, Grudzinski IP, Jakoniuk-Glodala K, Chlipala-Nitek I, Kaczynski B, Rowinski O (2014) Non-contrast-enhanced whole-body magnetic resonance imaging in the general population: the incidence of abnormal findings in patients 50 years old and younger compared to older subjects. PLoS ONE 9:e107840. https://doi.org/10.1371/journal.pone. 0107840
- Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daude H, Tretarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L (2017) Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol 131:525–546. https://doi.org/10.1007/s11060-016-2318-3
- Dho YS, Jung KW, Ha J, Seo Y, Park CK, Won YJ, Yoo H (2017) An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat 5:16–23. https:// doi.org/10.14791/btrt.2017.5.1.16
- Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL (2015) Epidemiology of meningiomas post-Public Law 107–206: the Benign Brain Tumor Cancer Registries Amendment Act. Cancer 121:2400–2410. https://doi.org/10.1002/cncr. 29379
- Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613–619. https://doi.org/10.1002/ cncr.20412
- Fuentes-Raspall R, Solans M, Roca-Barcelo A, Vilardell L, Puigdemont M, Del Barco S, Comas R, Garcia-Velasco A, Astudillo A, Carmona-Garcia MC, Marcos-Gragera R (2017) Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: results from the Girona Cancer Registry (1994–2013). Cancer Epidemiol 50:1–8. https://doi.org/10.1016/j. canep.2017.07.005
- Gibson LM, Paul L, Chappell FM, Macleod M, Whiteley WN, Al-Shahi Salman R, Wardlaw JM, Sudlow CLM (2018) Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis. BMJ 363:k4577. https://doi.org/10.1136/bmj. k4577
- Glasmacher SA, Thomas HS, Stirland L, Wilkinson T, Lumsden J, Langlands G, Waddell B, Holloway G, Thompson G, Pal S (2020) Incidental findings identified on head MRI for investigation of cognitive impairment: a retrospective review. Dement Geriatr Cogn Disord 48:123–130. https://doi.org/10.1159/000503956
- Gogos AJ, Young JS, Pereira MP, Morshed RA, Potts MB, Hervey-Jumper SL, Berger MS (2020) Surgical management of incidentally discovered low-grade gliomas. Journal of Neurosurgery:1–8. https://doi.org/10.3171/2020.6.Jns201296
- Haberg AK, Hammer TA, Kvistad KA, Rydland J, Muller TB, Eikenes L, Garseth M, Stovner LJ (2016) Incidental intracranial findings and their clinical impact; the HUNT MRI study in a general population of 1006 participants between 50–66 years. PLoS ONE 11:e0151080. https://doi.org/10.1371/journal.pone.0151080
- Hartwigsen GSH, Deuschl G, Jansen O, Ulmer S (2010) Incidental findings are frequent in young healthy individuals undergoing magnetic resonance imaging in brain research imaging studies: a prospective single-center study. J Comput Assist Tomogr 34:596–600

- Hedderich DM, Boeckh-Behrens T, Bauml JG, Menegaux A, Daamen M, Zimmer C, Bartmann P, Scheef L, Boecker H, Wolke D, Sorg C, Spiro JE (2020) Sequelae of premature birth in young adults : incidental findings on routine brain MRI. Clin Neuroradiol. https://doi.org/10.1007/s00062-020-00901-6
- Hegenscheid K, Seipel R, Schmidt CO, Volzke H, Kuhn JP, Biffar R, Kroemer HK, Hosten N, Puls R (2013) Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management. Eur Radiol 23:816–826. https://doi.org/10.1007/s00330-012-2636-6
- Hoffman S, Propp JM, McCarthy BJ (2006) Temporal trends in incidence of primary brain tumors in the United States, 1985– 19991. Neuro Oncol 8:27–37
- Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ (2014) In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J ClinEpidemiol 67:897–903
- Ikeda K, Kuwajima A, Hosozawa K, Anan K, Iwasaki Y, Kinoshita M, Takahashi I, Kumagai K, Kashihara H, Moroka M, Miura O, Tamura M (2002) Incidence of primary brain tumors in Japanese adults: brain checkup-based evidence. A crucial role omultiphasic health testings. HEP 29:772–774
- Illes J, Rosen A, Huang L, Goldstein RA, Raffin TA, Swan G, Atlas SW (2004) Ethical consideration of incidental findings on adult brain MRI in research. Neurology 63:888–890
- Kalasauskas D, Keric N, Abu Ajaj S, von Cube L, Ringel F, Renovanz M (2020) Psychological burden in meningioma patients under a wait-and-watch strategy and after complete resection is high-results of a prospective single center study. Cancers (Basel) 12. https://doi.org/10.3390/cancers12123503
- 27. Katzman GL, Dagher AP, Patronas NJ (1999) Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. JAMA 282:36–39
- Keuss SE, Parker TD, Lane CA, Hoskote C, Shah S, Cash DM, Keshavan A, Buchanan SM, Murray-Smith H, Wong A, James SN, Lu K, Collins J, Beasley DG, Malone IB, Thomas DL, Barnes A, Richards M, Fox N, Schott JM (2019) Incidental findings on brain imaging and blood tests: results from the first phase of Insight 46, a prospective observational substudy of the 1946 British birth cohort. BMJ Open 9:e029502. https://doi.org/10.1136/bmjop en-2019-029502
- Koncz R, Mohan A, Dawes L, Thalamuthu A, Wright M, Ames D, Lee T, Trollor J, Wen W, Sachdev P (2018) Incidental findings on cerebral MRI in twins: the older Australian twins study. Brain Imaging Behav 12:860–869. https://doi.org/10.1007/ s11682-017-9747-2
- Krampla W, Newrkla S, Pfisterer W, Jungwirth S, Fischer P, Leitha T, Hruby W, Tragl KH (2004) Frequency and risk factors for meningioma in clinically healthy 75-year-old patients: results of the Transdanube ageing study (VITA). Cancer 100:1208–1212. https://doi.org/10.1002/cncr.20088
- 31. Kumar R, Sachdev PS, Price JL, Rosenman S, Christensen H (2008) Incidental brain MRI abnormalities in 60- to 64-year-old community-dwelling individuals: data from the personality and total health through life study. Acta Neuropsychiatr 20:87–90. https://doi.org/10.1111/j.1601-5215.2008.00273.x
- 32. Laible M, Schoenberg SO, Weckbach S, Lettau M, Winnik E, Bischof J, Franke R, Reiser M, Kramer H (2012) Whole-body MRI and MRA for evaluation of the prevalence of atherosclerosis in a cohort of subjectively healthy individuals. Insights Imaging 3:485–493. https://doi.org/10.1007/s13244-012-0180-1
- Lee W-J, Chang L-B, Lee Y-C (2008) Incidental findings on brain MRI. N Eng J Med 358:853–854
- 34. Li S, Fang F, Cui M, Jiang Y, Wang Y, Kong X, Tian W, Fan M, Yuan Z, Chen J, Yang Q, Xue F, Wang J, Lu M, Wang X, Chen X, Jin L, Ye W (2019) Incidental findings on brain MRI among

Chinese at the age of 55–65 years: the Taizhou imaging study. Sci Rep 9:464. https://doi.org/10.1038/s41598-018-36893-0

- Li W, Zheng J, Wen W, Sachdev P Incidental brain findings on MRI in the general elderly population: the memory and aging study (MAS). In, 2010. European Congress of Radiology 2010. 10.1594/ecr2010/C-2712 (Jan 13, 2021)
- Li WC, Tu CH, Chao HT, Yeh TC, Chen LF, Hsieh JC (2015) High prevalence of incidental brain findings in primary dysmenorrhoea. Eur J Pain 19:1071–1074. https://doi.org/10.1002/ejp.639
- Lima GL, Zanello M, Mandonnet E, Taillandier L, Pallud J, Duffau H (2016) Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery. Neurosurg Rev 39:377–384. https://doi.org/10.1007/s10143-015-0675-6
- Lin DD, Lin JL, Deng XY, Li W, Li DD, Yin B, Lin J, Zhang N, Sheng HS (2019) Trends in intracranial meningioma incidence in the United States, 2004–2015. Cancer Med 8:6458–6467. https:// doi.org/10.1002/cam4.2516
- Lo GG, Ai V, Au-Yeung KM, Li KW, Chien D (2008) Magnetic resonance whole body imaging at 3 Tesla: feasibility and findings in a cohort of asymptomatic medical doctors. Hong Kong Med J 14:90–96
- 40. Louis DN (2016) WHO classification and grading of tumours of the central nervous system. WHO classification oft umours of the central nervous system. International Agency for Research on Cancer, Lyon
- Mandonnet E, de Witt HP, Pallud J, Bauchet L, Whittle I, Duffau H (2014) Silent diffuse low-grade glioma: toward screening and preventive treatment? Cancer 120:1758–1762. https://doi.org/10. 1002/cncr.28610
- Menzler K, Iwinska-Zelder J, Shiratori K, Jaeger RK, Oertel WH, Hamer HM, Rosenow F, Knake S (2010) Evaluation of MRI criteria (1.5 T) for the diagnosis of hippocampal sclerosis in healthy subjects. Epilepsy Res 89:349–354. https://doi.org/10.1016/j. eplepsyres.2010.02.010
- 43. Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y, Alphs H, Ladd SC, Warlow C, Wardlaw JM, Al-Shahi Salman R (2009) Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 339:b3016. https://doi.org/10.1136/bmj.b3016
- Mullally WJ, Hall KE (2018) Value of patient-directed brain magnetic resonance imaging scan with a diagnosis of migraine. Am J Med 131:438–441. https://doi.org/10.1016/j.amjmed.2017.10.042
- 45. Munn ZMS, Rittano D, Lisky K (2014) The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 3:123–128
- 46. Nagai Yamaki V, de Souza Godoy LF, AlencarBandeira G, Tavares Lucato L, Correa Lordelo G, Fontoura Solla DJ, Santana Neville I, Jacobsen Teixeira M, Silva Paiva W (2021) Dural-based lesions: is it a meningioma? Neuroradiology. https://doi.org/10. 1007/s00234-021-02632-y
- 47. Naing L, Winn T, Rusli BN (2006) Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci 1:9–14
- Nakasu S, Hirano A, Shimura T, Llena JF (1987) Incidental meningiomas in autopsy study. Surg Neurol 27:319–322
- Nakasu S, Nakasu Y (2020) Natural history of meningiomas: review with meta-analyses. Neurol Med Chir (Tokyo) 60:109– 120. https://doi.org/10.2176/nmc.ra.2019-0213
- Neugut AI, Sackstein P, Hillyer GC, Jacobson JS, Bruce J, Lassman AB, Stieg PA (2019) Magnetic resonance imagingbased screening for asymptomatic brain tumors: a review. Oncologist 24:375–384. https://doi.org/10.1634/theoncolog ist.2018-0177
- Ohgaki H, Kleiheus P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendrial gliomas. J Neuropathol Exp Neurol 64:479–489

- 52. Onizuka M, Suyama K, Shibayama A, Hiura T, Horie N, Miyazaki H (2001) Asymptomtic breain tumor detected at brain check-up. Neurol Med Chir (Tokyo) 41:431–435
- 53. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v56–v58
- Papanikolaou V, Khan MH, Keogh IJ (2010) Incidental findings on MRI scans of patients presenting with audiovestibular symptoms. BMC Ear Nose Throat Disord 10:6. https://doi.org/10.1186/ 1472-6815-10-6
- Rausing A, Ybo W, Stenflo J (1970) Intracranial meningioma a population study of ten years. Acta Neurol Scandinav 46:102–110
- 56. Reneman L, de Win MM, Booij J, van den Brink W, den Heeten GJ, Freling N, Majoie CB (2012) Incidental head and neck findings on MRI in young healthy volunteers: prevalence and clinical implications. AJNR Am J Neuroradiol 33:1971–1974. https://doi. org/10.3174/ajnr.A3217
- 57. Sandeman EM, Hernandez Mdel C, Morris Z, Bastin ME, Murray C, Gow AJ, Corley J, Henderson R, Deary IJ, Starr JM, Wardlaw JM (2013) Incidental findings on brain MR imaging in older community-dwelling subjects are common but serious medical consequences are rare: a cohort study. PLoS ONE 8:e71467. https://doi.org/10.1371/journal.pone.0071467
- Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rucker G (2019) Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods 10:476–483. https://doi.org/10.1002/jrsm. 1348
- Serag D, Ragab E (2020) Prevalence of incidentally discovered findings on brain MRI in adult Egyptian population. Egyptian Journal of Radiology and Nuclear Medicine 51. https://doi.org/ 10.1186/s43055-020-00187-1
- 60. Shah AH, Madhavan K, Sastry A, Komotar RJ (2013) Managing intracranial incidental findings suggestive of low-grade glioma:

learning from experience. World Neurosurg 80:e75-77. https://doi.org/10.1016/j.wneu.2012.06.021

- Trufyn J, Hill MD, Scott JN, Modi J, Ciura V, Frayne R, Goyal M, Lautner D, Bhayana D, Davenport WJ, Mah JK, Burton JM, Costello F (2014) The prevalence of incidental findings in multiple sclerosis patients. Can J Neurol Sci 41:49–52. https://doi.org/ 10.1017/s0317167100016255
- 62. Tsushima Y, Taketomi-Takahashi A, Endo K (2005) Prevalence of abnormal findings on brain magnetic resonance (MR) examinations in adult participants of brain docking. BMC Neurol 5:18. https://doi.org/10.1186/1471-2377-5-18
- Vazquez-Justes D, Sanahuja J, Diez J, Rubinat E, Begue R, Salas C, Vicandi C, Gil MI, Purroy F, Mauricio D (2020) Incidental findings on brain MRI in a cohort of diabetic patients. J Neuroradiol 47:343–348. https://doi.org/10.1016/j.neurad.2018.07.005
- Weber F, Knopf H (2006) Incidental findings in magnetic resonance imaging of the brains of healthy young men. J Neurol Sci 240:81–84. https://doi.org/10.1016/j.jns.2005.09.008
- 65. Wijnenga MMJ, Mattni T, French PJ, Rutten GJ, Leenstra S, Kloet F, Taphoorn MJB, van den Bent MJ, Dirven CMF, van Veelen ML, Vincent A (2017) Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neuroon-col 133:137–146. https://doi.org/10.1007/s11060-017-2418-8
- 66. Yue NC, Longstreth WT Jr, Elster AD, Jungreis CA, O'Leary DH, Poirier VC (1997) Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the cardiovascular health study. Radiology 202:41–46

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.